Literature DB >> 21804605

A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation.

C E Tognon1, M J Martin, A Moradian, G Trigo, B Rotblat, S-W G Cheng, M Pollard, E Uy, C Chow, J M Carboni, M M Gottardis, M Pollak, G B Morin, P H B Sorensen.   

Abstract

ETV6-NTRK3 (EN), a chimeric tyrosine kinase generated by t(12;15) translocations, is a dominantly acting oncoprotein in diverse tumor types. We previously showed that insulin-like growth factor 1 receptor (IGF1R) is essential for EN-mediated oncogenesis and that insulin receptor substrate 1 (IRS1) is constitutively tyrosine phosphorylated and bound by EN in transformed cells. Given that IRS1 is also an adapter for IGF1R, we hypothesized that IRS1 might localize EN to IGF1R at the membrane to activate phosphatidylinositol 3-kinase (PI3K)-Akt, which is critical for EN oncogenesis. In this study, we examined EN/IRS1/IGF1R complexes in detail. We find that both IRS1 and kinase active IGF1R are required for EN transformation, that tyrosine phosphorylated IRS1 is present in high molecular weight complexes with EN and IGF1R, and that EN colocalizes with IGF1R at the plasma membrane. Both IGF1R kinase activity and an intact cytoplasmic Y950 residue, the IRS1-docking site of IGF1R, are required, confirming the importance of the IGF1R/IRS1 interaction for EN oncogenesis. The dual specificity IGF1R and insulin receptor (INSR) inhibitor, BMS-536924, blocks EN transformation activity, cell survival and its interaction with IRS proteins, and induces a striking shift of EN proteins to smaller sized molecular complexes. We conclude that a tripartite complex of EN, IRS1 and IGF1R localizes EN to the membrane and that this is essential for EN-mediated transformation. These findings provide an explanation for the observed IGF1R dependency of EN transformation. Blocking IGF1R kinase activity may, therefore, provide a tractable therapeutic strategy for the many tumor types driven by the EN oncoprotein.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21804605     DOI: 10.1038/onc.2011.323

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

Review 1.  Detecting and targetting oncogenic fusion proteins in the genomic era.

Authors:  Monika A Davare; Cristina E Tognon
Journal:  Biol Cell       Date:  2015-04-07       Impact factor: 4.458

2.  Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas.

Authors:  Gregor Krings; Nancy M Joseph; Gregory R Bean; David Solomon; Courtney Onodera; Eric Talevich; Iwei Yeh; James P Grenert; Elizabeth Hosfield; Emily D Crawford; Richard C Jordan; Annemieke van Zante; Charles Zaloudek; Sandra J Shin; Yunn-Yi Chen
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

3.  CircVAPA promotes small cell lung cancer progression by modulating the miR-377-3p and miR-494-3p/IGF1R/AKT axis.

Authors:  Jinghan Hua; Xiaolin Wang; Liying Ma; Jingxin Li; Guozhen Cao; Shaobo Zhang; Wenchu Lin
Journal:  Mol Cancer       Date:  2022-06-06       Impact factor: 41.444

4.  Insulin-like growth factor 1 receptor stabilizes the ETV6-NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation.

Authors:  Cristina E Tognon; Bo Rafn; Naniye Malli Cetinbas; Takumi Kamura; Genny Trigo; Barak Rotblat; Fumihiko Okumura; Masaki Matsumoto; Christine Chow; Monika Davare; Michael Pollak; Thibault Mayor; Poul H Sorensen
Journal:  J Biol Chem       Date:  2018-06-14       Impact factor: 5.157

Review 5.  NTRK fusion-positive cancers and TRK inhibitor therapy.

Authors:  Emiliano Cocco; Maurizio Scaltriti; Alexander Drilon
Journal:  Nat Rev Clin Oncol       Date:  2018-12       Impact factor: 66.675

6.  Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance.

Authors:  Jonathan K M Lim; Alberto Delaidelli; Sean W Minaker; Hai-Feng Zhang; Milena Colovic; Hua Yang; Gian Luca Negri; Silvia von Karstedt; William W Lockwood; Paul Schaffer; Gabriel Leprivier; Poul H Sorensen
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-18       Impact factor: 11.205

Review 7.  IGF2/IGF1R Signaling as a Therapeutic Target in MYB-Positive Adenoid Cystic Carcinomas and Other Fusion Gene-Driven Tumors.

Authors:  Mattias K Andersson; Pierre Åman; Göran Stenman
Journal:  Cells       Date:  2019-08-16       Impact factor: 6.600

Review 8.  Oncogenic fusion proteins adopt the insulin-like growth factor signaling pathway.

Authors:  Haim Werner; Shilhav Meisel-Sharon; Ilan Bruchim
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

Review 9.  Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers.

Authors:  Aaron C Tan; Malinda Itchins; Mustafa Khasraw
Journal:  Int J Mol Sci       Date:  2020-02-19       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.